D. Western Therapeutics Institute (4576 JP) - Flurry of Pipeline Activity in 2023
Major milestones with high expectations coming in the next 2-3 years: 1) Phase IIb US trials for H-1337 as “first choice as a second-line Glaucoma...
405 Views
4Q Follow-Up -D. Western Therapeutics Institute (DWTI) | 4576
Major milestones with high expectations coming in the next 2-3 years: 1) Phase IIb US trials for H-1337 as “first choice as a second-line Glaucoma...
206 Views
3Q Follow-Up - D. Western Therapeutics Institute (DWTI) (4576 JP)
Major milestones with high expectations coming in the next 2-3 years: 1) Phase IIb US trials for H-1337 as “first choice as a second-line Glaucoma...
286 Views
2Q Follow-Up - D. Western Therapeutics Institute (DWTI) (4576 JP)
Flurry of pipeline activity continuing in the 3Q. Expedited development plans for DWR-2206, dual formula DW-1002 in the US, and commenced dosing of...
318 Views
News Flash - D. Western Therapeutics Institute (4576 JP)
DW-1002 licensee DORC announces decision to develop MEMBRANEBLUE-DUAL® in the US, received orphan drug designation from the US FDA for expedited...
165 Views